This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loibl, S. Articles by Kaufmann, M. Search for Related Content PubMed PubMed Citation Articles by Loibl, S. Articles by Kaufmann, M.

Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial

¹ Department of Obstetrics and Gynecology, J. W. Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
² German Breast Group, Neu-Isenburg, Germany
³ Praxis, Maximilianstrasse 50, 80538, München, Germany
⁴ St. Gertrauden Krankenhaus, Berlin, Germany
⁵ Department of Obstetrics and Gynecology, Otto-von-Guericke-University, Magdeburg, Germany
⁶ Department of Obstetrics and Gynecology, Klinikum Süd, Rostock, Germany
⁷ Department of Obstetrics and Gynecology, Christian-Albrecht-University, Kiel, Germany
⁸ Henriettenstiftung, Hannover, Germany
⁹ Klinikum Offenbach, Offenbach, Germany
¹⁰ HSK, Dr. Horst Schmidt Klinik, Wiesbaden, Germany
¹¹ Wolfartklinik, Waldstrasse 7, 82166, Gräfelfing, Germany

Correspondence: Address correspondence and reprint requests to: Sibylle Loibl, MD; E-mail: loibl{at}em.uni-frankfurt.de

Background: Neoadjuvant chemotherapy can increase the rate of breast-conserving surgery in patients with operable breast cancer. However, uncertainty remains regarding surgical procedures and predictors for successful breast-conserving surgery.

Methods: This study was an analysis of surgical data of a representative data subset of 607 patients enrolled in the GEPARDUO study. This prospective, multicenter, phase III study randomly assigned patients with operable breast cancer ( 2 cm) to neoadjuvant 8-week dose-dense doxorubicin plus docetaxel or a 24-week schedule of doxorubicin plus cyclophosphamide followed by docetaxel (AC-DOC).

Results: Breast conservation was attempted in 493 (81.2%) patients, but 43 patients eventually required mastectomy, thus resulting in a breast-conserving surgery rate of 74.1%. Breast-conserving re-excision was performed in 61 patients (12.4%). Factors associated with a significantly higher breast-conserving surgery rate were a prechemotherapy tumor size 40 mm, nonlobular histological characteristics, treatment with AC-DOC, clinical response, postchemotherapy tumor size 20 mm, and treatment in a larger center (>10 enrolled patients). Nonlobular histological characteristics and intraoperative frozen-section analysis for margin evaluation were associated with significantly lower reoperation rates (P = .015).

Conclusions: Breast conservation after neoadjuvant chemotherapy is feasible in most patients with operable breast cancer. For surgical planning, tumor characteristics and response to neoadjuvant chemotherapy should be taken into account. Improved breast-imaging modalities are necessary to improve detection of residual disease after neoadjuvant chemotherapy, especially when breast cancer is of lobular invasive histology. Margin assessment by intraoperative frozen-section analysis is helpful to avoid reoperation. To achieve an optimal result, an interdisciplinary surgical approach is important.

Key Words: Neoadjuvant therapy • Breast cancer • Breast conservation • Surgery • Re-excision

This article has been cited by other articles:

				G. von Minckwitz, S. Kummel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. D. Costa, C. Jackisch, et al. Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial J Natl Cancer Inst, April 16, 2008; 100(8): 542 - 551. [Abstract] [Full Text] [PDF]

				G. von Minckwitz, S. Kummel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. D. Costa, C. Jackisch, et al. Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study J Natl Cancer Inst, April 16, 2008; 100(8): 552 - 562. [Abstract] [Full Text] [PDF]

				M. Kaufmann, G. von Minckwitz, H. D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann. Onc., December 1, 2007; 18(12): 1927 - 1934. [Abstract] [Full Text] [PDF]